Skip to Content

Charles River Laboratories International Inc

CRL: XNYS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$926.00CdbhnxTgpqbztyz

Charles River Reports Solid Q1 Results; Maintaining FVE of $260 and Positive Outlook for 2022

Charles River reported solid first-quarter results in line with our expectations, and quarterly revenue reached $914 million, representing an increase of nearly 11% year over year. The company continues to benefit from strong booking activity and a robust backlog. We’ve updated our model with the latest results, and we maintain our $260 fair value estimate. Charles River is currently trading in 3-star territory about 7% below our fair value estimate. We maintain our narrow moat and stable trend ratings, which are based on the company’s robust competitive position and expansive offerings of preclinical services.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of CRL so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center